Test drug safety in adults with multiple system atrophy
Part of Brain & nervous system clinical trials.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your scan (DaTscan SPECT) shows Parkinson-type nerve loss in the brain’s striatum
- You have a diagnosis of multiple system atrophy (either parkinson-type or cerebellar-type)
- You can walk by yourself for at least 10 meters (about 30 feet)
- Your thinking/memory test (MoCA) must be 25 or higher
- No known genetic cause of Parkinsonism/ataxia in your family, and you don’t have that known cause
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This study tests whether a drug called butylphthalide can safely help people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions like blood pressure. Participating may help slow the progression of symptoms and improve quality of life.
This trial tests a new antibody therapy that may target and remove abnormal proteins in the brain linked to Multiple System Atrophy (MSA). It aims to see if the treatment is safe and whether it can help slow the progression of the disease.
This trial tests a new stem cell treatment for people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions. The treatment uses stem cells from healthy donors, which may help slow down the disease.
This trial tests whether a supplement called nicotinamide riboside (NR) can help people with rare forms of parkinsonism (PSP, MSA, or CBS). It is a double-blind study, meaning neither you nor the doctors will know if you are getting the real supplement or a placebo.
This study collects data from people with Parkinson's disease or multiple system atrophy (MSA) to better understand these conditions. You will have blood, saliva, optional spinal fluid tests, and brain scans (MRI, PET/SPECT).
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.